before scientific research of CagriSema uncovered that it assisted clients accomplish appreciably increased weight loss than semaglutide (Wegovy) did. although Lilly's Zepbound/Mounjaro topples Wegovy, it's possible that CagriSema could enter the market at the best time for Novo Nordisk to retain its In general Management from the obesity drug mark